Micar Innovation (Micar21)

Micar Innovation is a drug discovery factory. The company has found a niche where it is able to create a large societal impact by improving the quality of life through new blockbuster drug molecules for a large class of diseases. Micar Innovation focuses on non-clinical Proof-of-Concepts (POCs) in preclinical R&D and Hit-to-Lead (H2L) achievements in areas such as neuroscience, oncology, cardio-vascularity, dermatology, rare diseases. Micar21 is our drug discovery platform for small molecule drug candidates. The business model is based on licensing our intellectual property to commercial partners and on the creation new spin out companies.

MICAR INNOVATION (MICAR21) IS THE WINNER OF А PRESTIGIOUS AWARD FOR INNOVATIVE STARTUP ENTERPRISE OF THE YEAR 2018

Тhe 14th edition of the competition "Innovative Enterprise of the Year – 2018" took place during the National Innovation Forum on 6 December 2018. The Forum with the participation of the President of the Republic of Bulgaria Mr. Rumen Radev features the award ceremony of the Innovative Enterprise of the Year 2018 national contest. For Innovative New Startup Enterprise, Micar Innovation (Micar21) was awarded an honorary certificate.

Micar Innovation received the CIDIC/European Diplomatic, Economic & Academic Centre/ award for its well-chosen positioning in a complex and long value chain, where it can create key-value contributions by delivering no-clinical PoCs. The company can be described as a fountain of intellectual property and an IP broker for new pharma startups and the big pharma industry.

Micar Innovation is winner of the Best Biotech Startup 2017 award by the 4th CEE Startup Awards.

The good news is that the world renowned market analysis agency Roots Analysis published a study on the main players in "Computer-Aided Drug Discovery Services Market 2018-2030". Our company, Micar Innovation, is one of the world's 250 companies in the report alongside corporations such as Sanofi, Merck, etc.